---
title: "\"Performance\" Yuzhou Group's annual net profit is 24.93 billion RMB, turning losses into profits"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281229023.md"
description: "YUZHOU GROUP announced its 2025 annual performance, with revenue of RMB 6.751 billion, a year-on-year decrease of 30.5%. It recorded a net profit of RMB 24.93 billion, compared to a loss of RMB 11.967 billion in the previous year, turning from loss to profit; earnings per share were 2,414.22 cents. No dividend was declared. Excluding one-time gains from overseas debt restructuring of RMB 32.621 billion, the annual loss was RMB 9.718 billion"
datetime: "2026-03-31T18:27:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281229023.md)
  - [en](https://longbridge.com/en/news/281229023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281229023.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281229023.md) | [English](https://longbridge.com/en/news/281229023.md)


# "Performance" Yuzhou Group's annual net profit is 24.93 billion RMB, turning losses into profits

YUZHOU GROUP (01628.HK) announced its 2025 annual performance, with revenue of RMB 6.751 billion, a year-on-year decrease of 30.5%. It recorded a net profit of RMB 24.93 billion, compared to a loss of RMB 11.967 billion in the previous year, turning from loss to profit; earnings per share were 2,414.22 points. No dividend was declared.

Excluding one-time offshore debt restructuring gains of RMB 32.621 billion, the annual loss was RMB 9.718 billion

### 相關股票

- [YUZHOU GROUP (01628.HK)](https://longbridge.com/zh-HK/quote/01628.HK.md)

## 相關資訊與研究

- [TSMC's Supply Squeeze Through 2028 Could Be This Chipmaker's Big Break As AI Demand From Nvidia, Apple Surges](https://longbridge.com/zh-HK/news/281141442.md)
- [Iran Strikes Aluminum Plants as Gold & Silver Surge! Yields Collapse!](https://longbridge.com/zh-HK/news/281046479.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-HK/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-HK/news/281035263.md)